<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03606083</url>
  </required_header>
  <id_info>
    <org_study_id>PLIANTII</org_study_id>
    <nct_id>NCT03606083</nct_id>
  </id_info>
  <brief_title>Registry in Patients With Aorto-iliac or Iliac Aneurysms</brief_title>
  <acronym>PLIANTII</acronym>
  <official_title>Prospective Multicenter Registry to Examine the Real-world Performance of the E-liac Stent Graft System for Treatment of Uni- or Bilateral Aorto-iliac or Iliac Aneurysms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JOTEC GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JOTEC GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PLIANT II registry is undertaken to examine the real-world outcome after treatment of&#xD;
      consecutive patients with uni- or bilateral aorto-iliac or iliac aneurysms using the E-liac&#xD;
      Stent Graft System.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, patients will be observed who receive one or two E-liac Stent Graft(s) for&#xD;
      aorto-iliac or iliac aneurysms. The E-liac Stent Graft(s) will be implanted at the discretion&#xD;
      of the treating physician. Participating physicians will be asked to provide their&#xD;
      observations collected during routine care for patients he/she had decided to treat with the&#xD;
      E-liac Stent Graft System. Informed consent of the patients to allow the use of their&#xD;
      clinical records for the purpose of this observational study will be obtained before&#xD;
      intervention and before data are being collected.&#xD;
&#xD;
      The period of data collection will be 60 months starting from the intervention for each&#xD;
      patient. 100% verification of patient informed consent and essential study documents will be&#xD;
      performed at each study site. 60% of patient´s source documentation will be randomly&#xD;
      monitored.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2029</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from endoleak type I or III and patency of EIA and IIA on E-liac implantation side(s)</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of patients that reach the primary endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>24 hours</time_frame>
    <description>Rate of all cause mortality in peri-operative periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate</measure>
    <time_frame>prior to discharge / 30 days, 12, 24, 36, 60 months</time_frame>
    <description>Rate of survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aneurysm size</measure>
    <time_frame>12, 24, 36, 60 months</time_frame>
    <description>Rate of patients with decreasing, stable, increasing aneurysm size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary patency of EIA / IIA</measure>
    <time_frame>prior to discharge / 30 days, 12, 24, 36, 60 months</time_frame>
    <description>Rate of patients with primary patency of EIA / IIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary patency of EIA / IIA</measure>
    <time_frame>prior to discharge / 30 days, 12, 24, 36, 60 months</time_frame>
    <description>Rate of patients with secondary patency of EIA / IIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent graft dislodgement</measure>
    <time_frame>prior to discharge / 30 days, 12, 24, 36, 60 months</time_frame>
    <description>Rate of patients with stent graft dislodgement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoleak type I</measure>
    <time_frame>prior to discharge / 30 days, 12, 24, 36, 60 months</time_frame>
    <description>Rate of patients with infrarenal type Ia endoleak</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoleak type Ia in the CIA (isolated iliac aneurysm treatment)</measure>
    <time_frame>prior to discharge / 30 days, 12, 24, 36, 60 months</time_frame>
    <description>Rate of patients with infrarenal type Ia endoleak</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoleak type Ib in the CIA</measure>
    <time_frame>prior to discharge / 30 days, 12, 24, 36, 60 months</time_frame>
    <description>Rate of patients with endoleak type Ib in the CIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoleak type Ib in the EIA</measure>
    <time_frame>prior to discharge / 30 days, 12, 24, 36, 60 months</time_frame>
    <description>Rate of patients with endoleak type Ib in the EIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoleak type Ib in the IIA</measure>
    <time_frame>prior to discharge / 30 days, 12, 24, 36, 60 months</time_frame>
    <description>Rate of patients with endoleak type Ib in the IIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoleak type II</measure>
    <time_frame>prior to discharge / 30 days, 12, 24, 36, 60 months</time_frame>
    <description>Rate of patients with endoleak type II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoleak type III</measure>
    <time_frame>prior to discharge / 30 days, 12, 24, 36, 60 months</time_frame>
    <description>Rate of patients with endoleak type III</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent fracture</measure>
    <time_frame>prior to discharge / 30 days, 12, 24, 36, 60 months</time_frame>
    <description>Rate of patients with stent fracture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reintervention</measure>
    <time_frame>prior to discharge / 30 days, 12, 24, 36, 60 months</time_frame>
    <description>Rate patients with reintervention after E-liac Stent Graft implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Claudication</measure>
    <time_frame>prior to discharge / 30 days, 12, 24, 36, 60 months</time_frame>
    <description>Rate of patients with increasing, stable, decreasing claudication (walking distance without pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>prior to discharge / 30 days, 12, 24, 36, 60 months</time_frame>
    <description>Rate of patients with adverse events (product-related, procedure-related, aneurysm-related)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Vascular Aneurysm</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endovascular repair</intervention_name>
    <description>Endovascular repair of aorto-iliac or iliac aneurysms using an iliac branch device (IBD)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female patients with uni- or bilateral aorto-iliac or iliac aneurysm, treated with&#xD;
        the E-liac Stent Graft System.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 85 years&#xD;
&#xD;
          -  Patient must have an aorto-iliac or iliac aneurysm&#xD;
&#xD;
          -  Patient must have a unilateral or bilateral iliac aneurysm&#xD;
&#xD;
          -  Patient´s anatomy must be suitable for stent graft placement on preoperative angio CT&#xD;
             scan&#xD;
&#xD;
          -  Patient must be available for the appropriate follow-up times for the duration of the&#xD;
             study&#xD;
&#xD;
          -  Patient has been informed of the nature of the study, agrees to its provisions and has&#xD;
             signed the informed consent form prior to intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female of child bearing potential&#xD;
&#xD;
          -  Patients with ruptured iliac aneurysms&#xD;
&#xD;
          -  Patients with juxtarenal, pararenal or suprarenal aneurysms&#xD;
&#xD;
          -  Patients pretreated with Nellix (Endologix) or Altura (Lombard Medical)&#xD;
&#xD;
          -  Patient is currently participating in an investigational drug or device study that has&#xD;
             not completed the primary endpoint or that clinically interferes with the current&#xD;
             study endpoints&#xD;
&#xD;
          -  Patient with malignancy needing chemotherapy or radiation&#xD;
&#xD;
          -  Patients with life expectancy of less than 3 years&#xD;
&#xD;
          -  Patient minor or under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Brunkwall, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cologne University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heike Fischer, Dr.</last_name>
    <phone>+49 151 153 97 110</phone>
    <email>fischer.heike@cryolife.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Köln</name>
      <address>
        <city>Köln</city>
        <state>NRW</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Brunkwall, Prof.</last_name>
      <phone>+4922147832498</phone>
      <email>gefaesszentrum@uk-koeln.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Anton S, Wiedner M, Stahlberg E, Jacob F, Barkhausen J, Goltz JP. Initial Experience with the E-liac(®) Iliac Branch Device for the Endovascular Aortic Repair of Aorto-iliac Aneurysm. Cardiovasc Intervent Radiol. 2018 May;41(5):683-691. doi: 10.1007/s00270-017-1868-x. Epub 2018 Jan 3.</citation>
    <PMID>29299625</PMID>
  </reference>
  <reference>
    <citation>Mylonas SN, Rümenapf G, Schelzig H, Heckenkamp J, Youssef M, Schäfer JP, Ahmad W, Brunkwall JS; E-liac Collaborative Group. A multicenter 12-month experience with a new iliac side-branched device for revascularization of hypogastric arteries. J Vasc Surg. 2016 Dec;64(6):1652-1659.e1. doi: 10.1016/j.jvs.2016.04.065. Epub 2016 Aug 1.</citation>
    <PMID>27492764</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 29, 2018</study_first_submitted>
  <study_first_submitted_qc>July 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aorto-iliac</keyword>
  <keyword>iliac</keyword>
  <keyword>aneurysm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Iliac Aneurysm</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

